Nightstar Therapeutics (NASDAQ:NITE) shares hit a new 52-week high and low during trading on Friday . The stock traded as low as $10.01 and last traded at $12.19, with a volume of 62919 shares. The stock had previously closed at $11.89.
Several brokerages have commented on NITE. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Nightstar Therapeutics in a research note on Thursday. Mizuho restated a “buy” rating and issued a $20.00 target price on shares of Nightstar Therapeutics in a research note on Thursday. Finally, Chardan Capital began coverage on Nightstar Therapeutics in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 target price for the company. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $28.50.
The company has a market capitalization of $346.47 and a P/E ratio of -7.29.
WARNING: This report was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3335998/nightstar-therapeutics-nite-reaches-new-52-week-high-and-low-at-10-01.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.